Outlook Therapeutics Prepares for a Pivotal July: Shareholder Vote and FDA Decision Loom Over a Stock Already Up 144% YTD

Outlook Therapeutics stock surged 144% but faces shareholder vote on dilution and FDA decision on ONS-5010 for wet AMD by July 29.

Outlook Therapeutics has staged a stunning recovery from its 52-week low of $0.16 in March, surging more than ninefold as a string of positive regulatory developments ignited speculative buying. The biopharma stock closed Wednesday at $1.61, a 10.27% gain on the day, and has now advanced roughly 144% since the start of 2026. Yet for all the price momentum, the company enters July with a pair of make-or-break events that will test whether the rally has any foundation.

The first of those occurs in mid-July, when shareholders will vote on two radical capital-structure changes. The board is seeking approval to increase the authorized share count from 260 million to 600 million, and to execute a reverse stock split at a ratio between 1:10 and 1:50. Both measures are designed to give management more financial flexibility — the reverse split would push the share price above potential minimum-bid thresholds of other exchanges, while the authorized increase would allow further equity raises. But the immediate consequence for current holders would be severe dilution. The company ended March with just $7.7 million in cash and reported a net loss of $4.5 million for the most recent quarter, underscoring the urgency behind the proposals.

Thirteen days after the shareholder meeting, the U.S. Food and Drug Administration will deliver its verdict on ONS-5010 (LYTENAVA), the company's treatment for wet age-related macular degeneration. The agency accepted the resubmission as a Class-1 review, setting a PDUFA deadline of July 29, 2026. CEO Bob Jahr said the company was "very pleased that the FDA has accepted our resubmission for labeling review as the final step before potential approval." The efficacy of the therapy is no longer in dispute after a formal dispute-resolution process with the agency; only manufacturing and labeling details remain. If approved, ONS-5010 would become the first FDA-authorized ophthalmic formulation of bevacizumab for wet AMD, a market currently served only by off-label repackaged intravenous cancer drugs.

The stock's ascent has been fueled entirely by regulatory optimism, and investment bank BTIG has already signaled that the good news is priced in. The firm downgraded Outlook Therapeutics from Buy to Neutral in late June, citing limited upside from current levels given the financial hurdles. That caution is reflected in the technical picture: the shares trade 46% below their 52-week high of $2.97 set in August 2025, and are still down 17% over the trailing 12 months. The relative strength index stands at 64.9, approaching overbought territory, while the annualized 30-day volatility of 218% underscores the extreme speculation at play.

To shore up its balance sheet ahead of the FDA decision, Outlook recently completed a direct placement of roughly 8.5 million shares at $0.5855 apiece to its largest shareholder, GMS Ventures, raising approximately $5 million in gross proceeds. That infusion brought total cash to a still-modest level, even as the company begins to generate its first real revenue from European operations. Outlook already holds marketing approvals in the European Union and the United Kingdom, and sales have started in Germany and Austria. Quarterly revenue runs at about $1.4 million, with Cencora (formerly AmerisourceBergen) handling global distribution.

One overhanging risk has already been resolved. On June 26, Nasdaq confirmed that the company had regained compliance with the exchange's $1 minimum bid requirement after ten consecutive trading sessions above that threshold. The reprieve opens the door to a broader pool of institutional investors who cannot hold sub-dollar stocks, but it does nothing to address the dilution debate or the capital shortage.

For investors, the next few weeks present a tightly coupled binary outcome. A successful shareholder vote followed by a positive FDA decision could propel the company into the commercial stage, with a first-to-market product in the billion-dollar U.S. wet-AMD space. Failure on either front, however, would likely send the shares back into the volatility that defined the first half of 2026. With the stock's 50-day moving average at $0.83 and the 200-day at $0.92 — both far below the current price — the rally has already priced in a great deal of success. The question is whether the company can deliver it.